 CAMBRIDGE, Mass.--BUSINESS WIRE--Syros Pharmaceuticals NASDAQ:SYRS, a leader in the development of medicines that control the expression of genes, today announced that it plans to host a three-part key opinion leader KOL webcast series on its portfolio of investigational targeted therapies in hematology. The series will consist of presentations from Syros leaders, as well as KOLs, who will review recent progress for SY-1425 in newly diagnosed higher-risk myelodysplastic syndrome MDS and 